Zhejiang Tianyu Pharmaceutical's wholly owned subsidiary Zhejiang Nuode Pharmaceutical has had its trazodone hydrochloride tablets and edoxaban tosylate tablets tentatively selected for the 12th round of national centralized drug procurement. The trazodone hydrochloride tablets are in a 50 mg strength, while the edoxaban tosylate tablets come in 15 mg, 30 mg, and 60 mg strengths. The procurement period runs from the effective date of the selection results until December 31, 2029. Trazodone hydrochloride tablets are used to treat depression, with domestic sales of approximately 100,600 yuan in the first quarter of 2026. Edoxaban tosylate tablets are used for stroke prevention in non-valvular atrial fibrillation and for treating deep vein thrombosis, with sales of about 67,500 yuan in 2025 and roughly 103,800 yuan in the first quarter of 2026. The company stated that if the subsequent procurement contracts are successfully signed and implemented, it will help boost sales volume and market share, but there remains uncertainty regarding the signing of procurement agreements and the impact on company performance.
Zhejiang Tianyu Pharmaceutical Co LtdDrugs tentatively selected for national procurement, expected to boost sales volume and market share.
Subsidiary's drugs selected, likely to increase sales if contracts signed.